

B. Amendments to the Specification

Please replace paragraph [0041] of the specification with the following amended paragraph:

[0041] The results herein identify Sp17 (SEQ ID NO:1) as a novel CT antigen in MM. Therefore, studies were done to determine whether Sp17-specific CTL could be generated from the PBMC of a healthy previously unimmunized donor. In addition, studies were done to determine the relevance of these CTL in the context of killing of Sp17+ tumor cells, since this information would provide insight into whether Sp17 is processed, not only by normal cells pulsed with the recombinant protein, but also by Sp17-producing tumor cells. Most importantly, the results of these investigations provide the rationale and basis for the generation of donor-derived Sp17-specific CTL for donor lymphocyte infusion following allogeneic stem cell transplantation to augment GVM without eliciting GVHD.

Please replace paragraph [0046] of the specification with the following amended paragraph:

[0046] For additional background on sperm protein 17 (SEQ ID NO:1) see Lea et al. 1996; Lea et al. 1997; O’Rand and Widgren 1994; Lacy and Sanderson 1999; Lea et al. 1995; Wen et al. 1995; Lea et al. 1994; Lea et al. 1993; U.S. Patent No. 5,480,799; and U.S. Patent No. 5,820,861 (the contents of each of which are incorporated herein by reference). For additional background in immunotherapy, diagnostic applications and therapeutic applications in general relation to tumor or viral specific antigens, see U.S. Patent Nos. 5,695,994; 5,962,318; 5,980,896;

6,083,751; 6,165,725; and 6,171,796 (the contents of each of which are incorporated herein by reference).

Please insert the Sequence Listing, pages 1 to 1, at the end of the specification.